Recently, target therapy alone or combined with chemotherapy has been used to treat advanced NSCLC, and drugs targeting the EGFR and VEGF pathways have become new therapeutic options for lung cancer therapy. This evidence concerns the gene VEGFA and non-small cell lung carcinoma.